Physician profile
Patrick Mansky
NPI 1013931526
$2,347.49
in general payments reported to CMS, 2019-2025
18 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $176 · 2021: $1,798 · 2022: $20.79 · 2023: $46.93 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104 · Education: $99.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $104.31 |
| Education | $99.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,750.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $179.70 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $102.69 | 2019-2025 | |
| Astellas Pharma US INC | $99.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $78.31 | 2025 | Enhertu, Imfinzi |
| Glaxosmithkline, LLC. | $55.53 | 2020-2021 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Novocure INC. | $20.79 | 2022 | |
| Array Biopharma INC | $14.68 | 2020 | |
| Myriad Genetic Laboratories, INC. | $13.87 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.